Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-EN | Version v3-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2022-12-14 | 2022-10-12 |
| Drug Identification Number | 02229868 | 02229868 |
| Brand name | HYOSCINE BUTYLBROMIDE INJECTION SANDOZ STANDARD | HYOSCINE BUTYLBROMIDE INJECTION SANDOZ STANDARD |
| Common or Proper name | HYOSCINE BUTYLBR | HYOSCINE BUTYLBR |
| Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
| Ingredients | HYOSCINE BUTYLBROMIDE | HYOSCINE BUTYLBROMIDE |
| Strength(s) | 20MG | 20MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 1ML 10LIVI | 1ML 10LIVI |
| ATC code | A03BB | A03BB |
| ATC description | BELLADONNAAND DERIVATIVES, PLAIN | BELLADONNAAND DERIVATIVES, PLAIN |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2022-08-18 | 2022-08-18 |
| Estimated end date | 2022-12-23 | 2022-12-02 |
| Actual end date | 2022-12-13 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |